Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.24

Mkt cap

15M

Volume

80K

High

1.27

P/E Ratio

-0.60

52-wk high

7.33

Low

1.21

Div yield

N/A

52-wk low

1.10

Ascendiant Capital has maintained a Buy rating on NRX Pharmaceuticals and raised the price target from $43 to $44, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 5:58 pm

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, plans to acquire a network of ketamine treatment clinics with $30 million in financing. The expansion aims to treat conditions like depression and PTSD, projecting $100 million in annual revenue by 2025.

Portfolio Pulse from Rolando García

August 26, 2024 | 10:48 pm

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has secured non-dilutive debt funding to establish a $100M ketamine clinic network. This expansion aims to provide comprehensive mental health care services for conditions like suicidal depression and PTSD.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 12:02 pm

NRX Pharmaceuticals (NASDAQ:NRXP) reported a Q2 2024 GAAP EPS of $(0.75), missing the analyst consensus estimate of $(0.58) by 29.31%. However, this is an improvement from the $(1.21) per share loss in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:53 pm

NRx Pharmaceuticals has secured up to $16 million in convertible debt financing from an institutional investor. The funds will support the 2024 New Drug Application filing for its two lead products, NRX-100 and NRX-101, and will also be used to retire existing debt from Streeterville Capital.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:36 am

HC Wainwright & Co. analyst Vernon Bernardino maintains a Buy rating on NRX Pharmaceuticals (NASDAQ:NRXP) and adjusts the price target to $19 from $2 following a 1-10 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 7:42 pm

NRx Pharmaceuticals announced alignment with the FDA on the Pediatric Study Plan for NRX-100 (ketamine) aimed at treating suicidal depression in adolescents. The company remains on track to file the NDA for NRX-100 in Q4 2024, with an anticipated PDUFA date in Q2 2025.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:46 pm

NRx Pharmaceuticals announced that a Utah arbitrator denied Streeterville Capital's petition to prevent the spinoff of 49% of HOPE Therapeutics shares to NRx shareholders and to stop NRx from selling additional shares. The spinoff aims to provide value to NRx shareholders and potentially list HOPE Therapeutics on a national exchange.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:36 pm

NRx Pharmaceuticals has provided a shareholder update outlining potential revenue and profitability paths for 2025. The company anticipates revenue in 2024 from HOPE Therapeutics-branded clinics and in 2025 from the sales of NRX-100 (IV Ketamine) pending FDA approval, as well as NRX-101 for suicidal bipolar depression and akathisia.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:15 pm

NRx Pharmaceuticals plans to file two New Drug Applications (NDAs) in 2024 for NRX-101 and NRX-100, targeting bipolar depression, akathisia, and suicidal depression. These drugs have received Breakthrough Therapy and Fast Track Designations, respectively. Potential revenue from these drugs could exceed $150 per NRXP share. Additionally, HOPE Therapeutics is progressing towards a public listing.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 12:11 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.